1. Home
  2. FIVN vs DBVT Comparison

FIVN vs DBVT Comparison

Compare FIVN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five9 Inc.

FIVN

Five9 Inc.

HOLD

Current Price

$15.71

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$20.51

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIVN
DBVT
Founded
2001
2002
Country
United States
France
Employees
N/A
90
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
FIVN
DBVT
Price
$15.71
$20.51
Analyst Decision
Buy
Buy
Analyst Count
19
7
Target Price
$26.32
$31.75
AVG Volume (30 Days)
2.7M
213.3K
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
364.71
N/A
EPS
0.45
N/A
Revenue
$1,149,088,000.00
$4,151,000.00
Revenue This Year
$11.39
$65.50
Revenue Next Year
$10.00
$47.02
P/E Ratio
$36.13
N/A
Revenue Growth
10.28
N/A
52 Week Low
$15.70
$3.91
52 Week High
$31.75
$26.19

Technical Indicators

Market Signals
Indicator
FIVN
DBVT
Relative Strength Index (RSI) 36.61 45.16
Support Level N/A $20.23
Resistance Level $20.04 $25.00
Average True Range (ATR) 0.90 1.59
MACD -0.17 -0.24
Stochastic Oscillator 0.00 34.74

Price Performance

Historical Comparison
FIVN
DBVT

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: